EBS (Emergent Biosolutions, Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by EBS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-02 | Paul Anthony Williams | SVP, Products Business | Sell | — | — |
| 2026-06-10 | William Hartzel | SVP, Bioservices | F | — | — |
| 2026-06-10 | Coleen Glessner | EVP, Quality & Ethics, and CPL | F | — | — |
| 2026-06-10 | RICHARD S LINDAHL | EVP, Chief Financial Officer | F | — | — |
| 2026-06-10 | Paul Anthony Williams | SVP, Products Business | F | — | — |
| 2026-05-04 | Ronald Richard | Director | A | — | — |
| 2026-05-04 | Neal Franklin Fowler | Director | A | — | — |
| 2026-05-04 | Marvin L White | Director | A | — | — |
| 2026-05-04 | Donald W DeGolyer | Director | MIXED | — | — |
| 2026-05-04 | JOHN D FOWLER JR | Director | A | — | — |
| 2026-05-04 | Sujata Tyagi Dayal | Director | MIXED | — | — |
| 2026-05-04 | Zsolt Harsanyi | Chairman | A | — | — |
| 2026-05-04 | Keith Katkin | Director | MIXED | — | — |
| 2026-05-04 | Kathryn C Zoon | Director | MIXED | — | — |
| 2026-05-01 | RICHARD S LINDAHL | EVP, Chief Financial Officer | A | — | — |
| 2026-05-01 | Simon C Lowry | SVP, R&D, CMO | A | — | — |
| 2026-05-01 | JOSEPH C PAPA | President and CEO | A | — | — |
| 2026-05-01 | Jessica Perl | SVP, General Counsel, Corp Sec | A | — | — |
| 2026-05-01 | Coleen Glessner | EVP, Quality & Ethics, and CPL | A | — | — |
| 2026-05-01 | William Hartzel | SVP, Bioservices | A | — | — |
| 2026-05-01 | Paul Anthony Williams | SVP, Products Business | A | — | — |
| 2026-04-03 | Paul Anthony Williams | SVP, Products Business | Sell | — | — |
| 2026-03-06 | RICHARD S LINDAHL | EVP, Chief Financial Officer | H | — | — |
| 2026-03-05 | Paul Anthony Williams | SVP, Products Business | F | — | — |
| 2026-03-05 | Jessica Perl | SVP, General Counsel, Corp Sec | F | — | — |
| 2026-03-05 | William Hartzel | SVP, Bioservices | F | — | — |
| 2026-03-05 | RICHARD S LINDAHL | EVP, Chief Financial Officer | F | — | — |
| 2026-03-05 | JOHN D FOWLER JR | Director | A | — | — |
| 2026-03-05 | JOSEPH C PAPA | President and CEO | F | — | — |
| 2026-03-05 | Coleen Glessner | EVP, Quality & Ethics, and CPL | F | — | — |
| 2026-03-05 | Simon C Lowry | SVP, R&D, CMO | F | — | — |
| 2026-03-03 | RICHARD S LINDAHL | EVP, Chief Financial Officer | F | — | — |
| 2026-03-03 | Paul Anthony Williams | SVP, Products Business | F | — | — |
| 2026-03-03 | Coleen Glessner | EVP, Quality & Ethics, and CPL | F | — | — |
| 2026-02-10 | Paul Anthony Williams | SVP, Products Business | MIXED | — | — |
| 2026-02-10 | Coleen Glessner | EVP, Quality & Ethics, and CPL | MIXED | — | — |
| 2026-02-10 | RICHARD S LINDAHL | EVP, Chief Financial Officer | MIXED | — | — |
| 2026-02-10 | William Hartzel | SVP, Bioservices | MIXED | — | — |
| 2026-02-10 | Jessica Perl | SVP, General Counsel, Corp Sec | F | — | — |
| 2025-12-16 | Simon C Lowry | SVP, R&D, CMO | F | — | — |
| 2025-12-09 | Ronald Richard | Director | MIXED | — | — |
| 2025-11-13 | William Hartzel | SVP, Bioservices | F | — | — |
| 2025-11-12 | Donald W DeGolyer | Director | Sell | — | — |
| 2025-11-10 | Sujata Tyagi Dayal | Director | Sell | — | — |
| 2025-10-17 | RICHARD S LINDAHL | EVP, Chief Financial Officer | F | — | — |
| 2025-10-16 | Coleen Glessner | EVP, Quality & Ethics, and CPL | Sell | — | — |
| 2025-08-18 | Kathryn C Zoon | Director | Sell | — | — |
| 2025-08-13 | Donald W DeGolyer | Director | Sell | — | — |
| 2025-07-15 | William Hartzel | SVP, Bioservices | F | — | — |
| 2025-06-10 | Paul Anthony Williams | SVP, Products Business | F | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 4,344,250 | — |
| — | 10%+ Owner | 2,265,043 | — |
| — | — | 1,409,464 | — |
| — | Chairman | 1,343,405 | — |
| — | — | 1,269,390 | — |
| — | Director | 601,731 | — |
| — | President and CEO | 493,153 | — |
| — | EVP, Chief Financial Officer | 374,083 | — |
| — | President and CEO | 365,520 | — |
| — | EVP, Quality & Ethics, and CPL | 202,201 | — |
| — | EVP, Ext Aff, GC, Corp Sec | 186,382 | — |
| — | SVP, Bioservices | 185,558 | — |
| — | SVP, R&D, CMO | 177,914 | — |
| — | SVP, General Counsel, Corp Sec | 165,286 | — |
| — | Director | 160,847 | — |
| — | SVP, Products Business | 159,098 | — |
| — | Chairman | 149,076 | — |
| — | CEO | 144,553 | — |
| — | Director | 139,098 | — |
| — | Director | 129,721 | — |
| — | EVP, Business Operations | 125,167 | — |
| — | Director | 123,761 | — |
| — | Director | 114,324 | — |
| — | Director | 113,839 | — |
| — | Director | 111,775 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the EBS quote page; the site-wide leaderboard is on the insider transactions hub.